2King’s College London, Divisions of Reproduction and Endocrinology and Health and Social Care Research, St Thomas’ Hospital, London SE1 7EH

ellen.wright{at}kcl.ac.uk

Green and colleagues report the risk of various gastrointestinal cancers with oral bisphosphonates.1 Using a similar dataset from the same database, we independently compared bisphosphonate prescribing in cases of upper gastrointestinal cancer with that in controls from 1995 (when alendronate was first licensed) to 2007.

The odds of being a case increased 1.17 times for those taking bisphosphonates (odds …